title: Imatinib mesylate for palliative second-line treatment of advanced biliary tract cancer: a bicentric phase II study.
authors.forename: Annekathrin
authors.initials: A
authors.lastname: Roth
authors.forename: Eberhard
authors.initials: E
authors.lastname: Schleyer
authors.forename: Konrad
authors.initials: K
authors.lastname: Schoppmeyer
authors.forename: Regine
authors.initials: R
authors.lastname: Kluge
authors.forename: Christian
authors.initials: C
authors.lastname: Wittekind
authors.forename: Joachim
authors.initials: J
authors.lastname: Mössner
authors.forename: Marcus
authors.initials: M
authors.lastname: Wiedmann
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides; D001650:Bile Duct Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018281:Cholangiocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D005260:Female; D005706:Gallbladder Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010166:Palliative Care; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate